Kelyniam Global, Inc.

Equities

KLYG

US4883591004

Advanced Medical Equipment & Technology

Market Closed - OTC Markets Other stock markets 20:06:41 15/05/2024 BST			5-day change	1st Jan Change
0.065 ^USD	-15.03%		+36.84%	+5.69%

04-02	Kelyniam Global Announces NEOS Surgery Cranial LOOP? Fixation System Receives 510(k) Clearance from the FDA for use with Finceramica's CustomizedBone? Hydroxyapatite Cranial Implant	CI
03-17	Kelyniam Global, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Kelyniam Global, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021

May 18, 2021 at 10:47 pm

Kelyniam Global, Inc. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced sales was USD 664,353. Operating income was USD 13,806. Net loss was USD 7,928.

Latest news about Kelyniam Global, Inc.

Kelyniam Global Announces NEOS Surgery Cranial LOOP? Fixation System Receives 510(k) Clearance from the FDA for use with Finceramica's CustomizedBone? Hydroxyapatite Cranial Implant	04-02	CI
Kelyniam Global, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-16	CI
Kelyniam Global, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	12-10	CI
Kelyniam Global, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	17/05/23	CI
Kelyniam Global, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	19/03/23	CI
Kelyniam Global, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022	13/11/22	CI
Singular Health Group Ltd Appoints Kelyniam Global, Inc. and CG1 Solutions as Agents	08/11/22	CI
Kelyniam Global, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	07/08/22	CI
Kelyniam Global, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	08/05/22	CI
Kelyniam Global, Inc. Provides Earnings Guidance for the Year 2022	14/02/22	CI
Kelyniam Global, Inc., Announces Strategic Licensing Agreement with Fin-ceramica faenza spa to Market Hydroxyapatite Cranial Implant in the U.S	22/12/21	CI
United States Patent and Trademark Office Issues Notification For Patent Covering the Kelyniam Global's Integrated Fixation Tabs, Currently Marketed as Ifs Tabs or Kwiktabs	02/12/21	CI
Kelyniam Global, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2021	08/11/21	CI
Kelyniam Global, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	18/05/21	CI
Kelyniam Global, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2020	16/11/20	CI
Kelyniam Global, Inc. Not to Provide Financial Results Guidance for the Fourth Quarter of 2020	16/11/20	CI
Kelyniam Global, Inc. Reports Earnings Results for the Half Year Ended June 30, 2020	23/08/20	CI
Kelyniam Global, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	18/06/20	CI
Kelyniam Global Provides Earnings Guidance for the Second Quarter of 2020	18/06/20	CI
Kelyniam Global, Inc. Announces Executive Appointments	07/05/20	CI
Kelyniam Global Announces Distribution Agreement with SurgicalOne	17/12/19	CI
Kelyniam Global, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2019	16/12/19	CI
Kelyniam Global, Inc. Reports Earnings Results for the Half Year Ended June 30, 2019	18/10/19	CI
Kelyniam Global, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019	08/08/19	CI
Kelyniam Global Announces Distribution Agreement with Bioplate	09/07/19	CI

Chart Kelyniam Global, Inc.

Duration

Period

More charts

Company Profile

Kelyniam Global, Inc. is a custom design-to-build medical device manufacturing company. The Company specializes in the delivery of cranial implant technologies to neurologically dependent patients. The Company is engaged in the production of custom prosthetics utilizing computer-aided design and computer-aided manufacturing of medical-grade polymers. Its Engineering Division uses Bio-Computer Aided Design (CAD) Computer Aided Manufacturing (CAM) technology to provide replicated cranial implants to replace damaged bone structures. Its product, PEEK-Optima, is engineered for biocompatibility. Derived from the patientâs computed tomography (CT) data, the Companyâs 3D BIO-CAD/CAM software is used to transfer the details found on the edge of the defect directly to the implant edge. Its K-Plans include ke24, ke72 and kp5day. The Companyâs emergency plan, ke24, provides precision-replicated, patient-specific cranial implants in approximately 24 hours.

Sector

Advanced Medical Equipment & Technology

Calendar

24/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
KELYNIAM GLOBAL, INC.	+5.69%	2.27M
THERMO FISHER SCIENTIFIC	+12.85%	227B
DANAHER CORPORATION	+13.88%	192B
INTUITIVE SURGICAL, INC.	+18.39%	136B
BOSTON SCIENTIFIC CORPORATION	+28.78%	108B
SIEMENS HEALTHINEERS AG	+1.67%	64.07B
EDWARDS LIFESCIENCES CORPORATION	+18.24%	52.1B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+7.04%	51.87B
AGILENT TECHNOLOGIES, INC.	+10.83%	44.33B
GE HEALTHCARE TECHNOLOGIES INC.	+5.94%	36.75B

Other Advanced Medical Equipment & Technology